Diabetes Technol Ther. 2010 Sep;12(9):679-84. doi: 10.1089/dia.2010.0015.
The evaluation of patient-reported outcomes (e.g. impact, satisfaction) is important in trials of continuous glucose monitoring (CGM). We evaluated psychometric properties of the CGM Satisfaction Scale (CGM-SAT) and the Glucose Monitoring Survey (GMS).
CGM-SAT is a 44-item scale on which patients (n=224) or parents (n=102) rated their experience with CGM over the prior 6 months. GMS is a 22-item scale on which patients (n=447) or parents (n=221) rated the blood glucose monitoring system they were using (home glucose meter with or without CGM) at baseline and 6 months.
The alpha coefficient for the CGM-SAT was > or = 0.94 for all respondents and for the GMS was > or = 0.84 for all respondents at baseline and 6 months. Parent-youth agreement was 0.52 for the CGM-SAT at 6 months and 0.24 and 0.20 for the GMS at baseline and 6 months for the Standard Care Group, respectively. Test-retest reliability of the GMS at 6 months for controls was r=0.76 for adult patients, 0.63 for pediatric patients, and 0.43 for parents. Factor analysis isolated measurement factors for the CGM-SAT labeled Benefits of CGM and Hassles of CGM, accounting for 33% and 9% of score variance, respectively. For the GMS, two factors emerged: Glucose Control and Social Complications, accounting for 28% and 9% of variance, respectively. Significant correlations of CGM-SAT with frequency of CGM use between 6 months and baseline and GMS with frequency of conventional daily self-monitoring of blood glucose at baseline support their convergent validity.
The CGM-SAT and GMS are reliable and valid measures of patient-reported CGM outcomes.
在连续血糖监测（CGM）试验中，评估患者报告的结局（例如影响、满意度）非常重要。我们评估了 CGM 满意度量表（CGM-SAT）和血糖监测调查（GMS）的心理测量特性。
CGM-SAT 是一个 44 项的量表，患者（n=224）或家长（n=102）在过去 6 个月内对 CGM 的体验进行了评分。GMS 是一个 22 项的量表，患者（n=447）或家长（n=221）在基线和 6 个月时对他们正在使用的血糖监测系统（带或不带 CGM 的家用血糖仪）进行了评分。
所有受访者的 CGM-SAT 的 alpha 系数均>或=0.94，GMS 的 alpha 系数在基线和 6 个月时均>或=0.84。6 个月时，家长与青少年的 CGM-SAT 一致性为 0.52，基线和 6 个月时，标准护理组的 GMS 分别为 0.24 和 0.20。对照组的 GMS 在 6 个月时的测试重测信度为成人患者 r=0.76、儿科患者 r=0.63、家长 r=0.43。因素分析为 CGM-SAT 分离出测量因子，分别标记为 CGM 的益处和 CGM 的麻烦，分别占评分变异的 33%和 9%。对于 GMS，出现了两个因素：血糖控制和社会并发症，分别占变异的 28%和 9%。CGM-SAT 与 6 个月和基线之间 CGM 使用频率的显著相关性，以及 GMS 与基线时常规每日自我监测血糖频率的相关性，支持它们的收敛效度。
CGM-SAT 和 GMS 是评估患者报告的 CGM 结局的可靠和有效的工具。
